CJC-1295 No DAC Peptide: What It Is and How It Works

CJC-1295 no DAC is a modified growth hormone-releasing hormone (GHRH) analog that signals the pituitary gland to release growth hormone in short, natural pulses. It lacks the Drug Affinity Complex (DAC) built into the long-acting version, so its half-life is measured in minutes instead of days. CJC-1295 no DAC is a research chemical and is not FDA-approved for human use in the United States.

What Is CJC-1295 No DAC?

CJC-1295 no DAC is also sold under the names Mod GRF (1-29) and Modified GRF 1-29. It is a 29-amino-acid peptide modeled on the first 29 residues of natural GHRH, with four substitutions added to slow enzymatic breakdown in the bloodstream.

Rather than supplying growth hormone directly, the peptide binds GHRH receptors on somatotroph cells in the anterior pituitary and prompts the body to release its own GH. That means it depends on a functioning pituitary to have any effect at all.

• Peptide class: GHRH analog
• Molecular target: GHRH receptor
• Typical form: Lyophilized powder reconstituted with bacteriostatic water
• Legal status in the US: Research chemical only, not an approved drug

CJC-1295 DAC vs No DAC: What Actually Changes

The cjc-1295 dac vs no dac comparison comes down to a single structural addition. The DAC version carries a maleimidopropionic acid linker that binds the peptide to albumin in the bloodstream, which keeps it circulating for days rather than minutes.

Feature	CJC-1295 DAC	CJC-1295 No DAC
Other names	CJC-1295 with DAC	Mod GRF (1-29), Modified GRF 1-29
Albumin binding	Yes	No
Half-life	Roughly 6-8 days	Roughly 30 minutes
GH release pattern	Continuous elevation	Short pulses
Dosing frequency discussed	Once weekly or every few days	One to three times daily

The practical consequence is the shape of the growth hormone signal. CJC-1295 DAC creates a steady, elevated baseline, while the no-DAC form mimics the body's natural bursts. Researchers interested in pulsatile GH release generally work with the no-DAC version.

CJC-1295 No DAC Half-Life and Dosing in Research

The cjc-1295 no dac half-life is roughly 30 minutes in circulation, although the growth hormone pulse it triggers can persist longer. That short window is why research protocols usually involve multiple administrations per day rather than one weekly injection.

Controlled human data on this peptide is thin, so any cjc-1295 no dac dosage circulating online is anecdotal rather than established. Figures commonly discussed in research communities sit between 100 mcg and 300 mcg per administration, one to three times per day, often timed around fasting or sleep.

Parameter	Anecdotal range discussed in forums
Per administration	100-300 mcg
Frequency	1-3 times daily
Typical timing	Before bed or in a fasted state
Cycle length discussed	8-12 weeks

None of those numbers come from a regulatory review or a large randomized trial. They are discussion points, not instructions.

Stacking CJC-1295 No DAC With Ipamorelin

CJC-1295 no DAC is most often discussed alongside ipamorelin, a selective ghrelin-receptor agonist that triggers GH release through a different pathway. Pairing a GHRH analog with a ghrelin mimetic is thought to amplify the natural pulse more than either compound could alone.

The cjc-1295 ipamorelin no dac benefits most frequently reported in user accounts are better sleep, faster recovery between training sessions, and gradual changes in body composition. Those reports are self-selected and unverified, and no large controlled trial confirms them.

Blended vials change the arithmetic. A cjc-1295 no dac ipamorelin 10mg blend dosage usually refers to 5 mg of each peptide in one vial, so a fixed syringe volume always delivers a 1:1 ratio. That is convenient, but it removes the ability to adjust one peptide independently of the other.

How Tesamorelin Compares

Anyone weighing tesamorelin vs cjc-1295 no dac should note the approval gap first. Tesamorelin is FDA-approved as Egrifta for reducing excess visceral fat in adults with HIV-associated lipodystrophy. CJC-1295 no DAC has no approved human indication.

Feature	Tesamorelin	CJC-1295 No DAC
FDA status	Approved for HIV-associated lipodystrophy	Not approved for human use
Half-life	Roughly 26-38 minutes	Roughly 30 minutes
Receptor	GHRH receptor	GHRH receptor
Common research focus	Visceral fat reduction	GH pulsatility and stacking
How it is obtained	Prescription	Research chemical supplier

Both peptides act on the same receptor, so combining them would not add a new mechanism of action. Most researchers treat them as alternatives rather than partners.

Safety, Legality, and Practical Cautions

CJC-1295 no DAC is not FDA-approved for human use, and selling it with drug-like health claims violates US law. Personal possession is not automatically illegal, but that does not make the peptide safe.

• Reported side effects: Injection-site irritation, flushing, headache, and water retention appear repeatedly in user accounts.
• Blood sugar: Growth hormone affects glucose metabolism, so people with diabetes or prediabetes face added risk.
• Purity: Online peptide vendors vary widely, and a certificate of analysis can be fabricated.
• Long-term unknowns: Safety data in healthy adults using this peptide does not exist.

Anyone considering CJC-1295 no DAC should talk with a healthcare professional first. Self-dosing an unapproved research chemical carries risks that no forum thread can quantify.

COMMON QUESTIONS

Frequently Asked Questions

Is CJC-1295 no DAC the same as Mod GRF 1-29?

Yes, for practical purposes they are the same peptide. Mod GRF (1-29) and Modified GRF 1-29 are alternative names for CJC-1295 without the Drug Affinity Complex. Both refer to a 29-amino-acid GHRH analog with four substitutions that resist enzymatic breakdown.

Is CJC-1295 no DAC FDA-approved?

No. CJC-1295 no DAC is not FDA-approved for any human use and is sold as a research chemical in the United States. Marketing it with drug-like claims is illegal, even though the FDA has not approved it as a treatment for any condition.

How long does CJC-1295 no DAC stay active?

Its half-life is roughly 30 minutes in circulation, which is far shorter than the 6-8 day half-life of CJC-1295 DAC. The growth hormone pulse it triggers can last longer than the peptide itself, which is why research discussions often describe dosing one to three times daily.